Susceptibility to beta-lactam antibiotics in septicemia isolates from twenty-nine European laboratories. European Study Group on Antibiotic Resistance.
In 1984 the European Study Group on Antibiotic Resistance (ESGAR) consecutively collected gram-negative bacilli and staphylococci blood isolates and performed susceptibility testing with 11 antibiotics using the microdilution method. In all 2,578 isolates were collected: 68% gram-negative bacilli and 32% staphylococci. The MICs of ampicillin and cefazoline for the susceptible gram-negative bacilli were 1-8 micrograms/ml; of piperacillin less than or equal to 0.5-4; of Sch 34343, cefotaxime, moxalactam, ceftazidime and aztreonam less than or equal to 0.5-2 micrograms/ml; of cefoxitin, cefuroxime and cefamandole less than or equal to 0.5-8 micrograms/ml. For susceptible staphylococci the MICs of cefazoline and cefuroxime were less than or equal to 0.5-1 micrograms/ml, and of cefoxitin, moxalactam, ceftazidime and cefotaxime, less than or equal to 0.5-32 micrograms/ml. The resistance levels varied between laboratories and countries, being lower in Northern Europe. In clinical protocols on patients with gram-negative septicemia from whom cefazoline-resistant strains were isolated, cefotaxime was the beta-lactam most commonly used (12%). In protocols on patients with staphylococcal septicemia from whom gentamicin-resistant or cefazoline-resistant strains were isolated, the most commonly used beta-lactam was cloxacillin (6%).
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects; D005060:Europe; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D011549:Pseudomonas / Q000187:drug effects; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology*; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects*; D047090:beta-Lactams
D000900:Anti-Bacterial Agents; D047090:beta-Lactams